Pub. Date : 2000 Sep
PMID : 16049868
14 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Insulin glargine (Aventis Pharma). | Insulin Glargine | insulin | Homo sapiens |
| 2 | Insulin glargine is a biosynthetic human insulin analog which has been developed by Aventis Pharma (formerly Hoechst Marion Roussel, HMR), for the treatment of types I and II diabetes. | Insulin Glargine | insulin | Homo sapiens |
| 3 | Insulin glargine is a biosynthetic human insulin analog which has been developed by Aventis Pharma (formerly Hoechst Marion Roussel, HMR), for the treatment of types I and II diabetes. | Insulin Glargine | insulin | Homo sapiens |
| 4 | In April 1999, HMR filed insulin glargine for approval in both Europe and the US [322507]. | Insulin Glargine | insulin | Homo sapiens |
| 5 | In April 2000, the FDA approved insulin glargine (as Lantus) for the treatment of adult patients with type II diabetes mellitus, who require basal insulin for the control of hyperglycemia, and for adult and pediatric patients with type I diabetes mellitus [363836]. | Insulin Glargine | insulin | Homo sapiens |
| 6 | In April 2000, the FDA approved insulin glargine (as Lantus) for the treatment of adult patients with type II diabetes mellitus, who require basal insulin for the control of hyperglycemia, and for adult and pediatric patients with type I diabetes mellitus [363836]. | Insulin Glargine | insulin | Homo sapiens |
| 7 | In April 2000, the FDA approved insulin glargine (as Lantus) for the treatment of adult patients with type II diabetes mellitus, who require basal insulin for the control of hyperglycemia, and for adult and pediatric patients with type I diabetes mellitus [363836]. | Insulin Glargine | insulin | Homo sapiens |
| 8 | In April 2000, the FDA approved insulin glargine (as Lantus) for the treatment of adult patients with type II diabetes mellitus, who require basal insulin for the control of hyperglycemia, and for adult and pediatric patients with type I diabetes mellitus [363836]. | Insulin Glargine | insulin | Homo sapiens |
| 9 | In June 2000, the EMEA approved insulin glargine for the treatment of both type I and II diabetes [370984]. | Insulin Glargine | insulin | Homo sapiens |
| 10 | Insulin glargine is in phase III trials in Japan as a substitute for basal insulin in the treatment of Type I diabetes [216445]. | Insulin Glargine | insulin | Homo sapiens |
| 11 | Two formulations of insulin glargine with zinc have also been tested in phase I trials. | Insulin Glargine | insulin | Homo sapiens |
| 12 | Insulin glargine was designated as a medium priority project by HMR, which means the project had been set tight deadlines which if not achieved, would have resulted in discontinuation [221118]. | Insulin Glargine | insulin | Homo sapiens |
| 13 | In April 2000, Novo Nordisk filed a complaint in Germany against Aventis claiming that the production and sale of insulin glargine infringes two German patents held by Novo Nordisk [364362]. | Insulin Glargine | insulin | Homo sapiens |
| 14 | In July 2000, Credit Lyonnais Securities Europe predicted that insulin glargine was likely to enjoy a strong competitive position for several years in Europe and the US, following launch in these territories during 2000, while it was predicted that a registration dossier would be submitted in Japn in 2002. | Insulin Glargine | insulin | Homo sapiens |